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Purpose: This pilot study investigated whether high-resolution spectral-domain optical coherence 
tomography (SD-OCT) could detect differences in inner retinal layer (IRL), peripapillary retinal 
nerve fiber layer (RNFL), and macular thickness between patients with Parkinson’s disease (PD) 
and controls.
Methods: Both eyes of patients with PD and age-matched controls were imaged with the 
Heidelberg Spectralis® HRA + OCT. RNFL, IRL, and macular thickness were measured for each 
eye using Heidelberg software. These measurements were compared with validated,   published 
normal values for macular and RNFL thickness, and compared with matched controls for IRL 
thickness.
Results: Eighteen eyes from nine subjects with PD and 19 eyes of 16 control subjects were 
  evaluated using SD-OCT. The average age of PD patients was 64 years with a range of 
52–75 years. The average age of controls was 67 years with a range of 50–81 years. No   significant 
reduction in IRL thickness was detected between PD patients and age-matched controls at 
13 points along a 6 mm horizontal section through the fovea. No significant difference in RNFL 
thickness was detected between PD patients and published normal values. Overall average RNFL 
thickness was 97 μm for PD patients, which exactly matched the normative database value. 
However, significant differences in macular thickness were detected in three of nine subfields 
between PD subjects and published normal values. In PD subjects, the outer superior subfield 
was 2.8% thinner (P = 0.026), while the outer nasal and inner inferior subfields were 2.8%   
(P = 0.016) and 2.7% (P = 0.001) thicker compared to published normal values.
Conclusion: In this pilot study, significant differences in macular thickness were detected in 
three of nine subfields by SD-OCT. However, SD-OCT did not detect significant reductions in 
peripapillary RNFL and IRL thickness between PD patients and controls. This suggests that 
macular thickness measurements by SD-OCT may potentially be used as an objective, nonin-
vasive, and easily quantifiable in vivo biomarker in PD. Larger, longitudinal studies are needed 
to explore these relationships further.
Keywords: Parkinson’s disease, spectral-domain optical coherence tomography, nerve fiber 
layer thickness, macular thickness, inner retinal layer thickness
Introduction
Parkinson’s disease (PD), the second most common neurodegenerative disease, is a 
progressive disorder with selective dopaminergic neuronal loss, mainly in the sub-
stantia nigra. It was first described by James Parkinson in 1817.1 Visual symptoms 
are common in PD, and include reduced spatial contrast sensitivity, motion perception 
abnormalities, color deficiency, and visual hallucinations. Dopaminergic neuronal cells 
have been identified in the inner nuclear layer and inner plexiform layers of the human Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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retina.2 Histopathologic studies on postmortem Parkinson’s 
patients never treated with levodopa showed significantly 
lower retinal dopamine concentrations than controls or indi-
viduals with PD whose death occurred less than 15 hours after 
their last dose.3 The role of retinal dopaminergic neuronal 
cells in visual function has been well studied in both human 
and primate models, and these cells appear to modulate the 
receptive fields of retinal ganglion cells to provide spatial 
contrast sensitivity and color vision.4–6
Thinning of the retinal nerve fiber layer (RNFL), the 
inner retinal layer (IRL), and macular thickness have been 
documented in several small studies, and it has been proposed 
that this may correlate with loss of these dopaminergic cells 
and progression of functional visual abnormalities in PD 
patients (Figure 1).7–10
Optical coherence tomography (OCT) is a noninvasive 
retinal imaging modality that can rapidly provide high-
resolution, cross-sectional images of the retina. It is the best 
modality for measuring retinal thickness and volume, and 
can precisely quantify changes in the retina through com-
parative imaging.
The primary goal of this pilot project was to investigate 
RNFL thickness, macular thickness, and IRL thickness in 
patients with PD using high-resolution spectral domain OCT 
(SD-OCT) and to compare them with unaffected control 
subjects to determine if reductions in the thickness of these 
structures could be detected in PD patients.
Methods
This study was approved by the institutional review board at 
Weill Cornell Medical College and New York   Presbyterian 
Hospital, and adhered to the tenets of the Declaration of 
Helsinki. Consecutive patients diagnosed with PD who 
were referred to our clinic for ophthalmic evaluation, as well 
as age-matched controls, were included. All patients and 
  controls underwent a dilated fundus examination. Patients 
with a history of glaucoma, optic neuropathy, age-related 
macular degeneration, diabetic retinopathy, or other signifi-
cant retinal or optic nerve diseases were excluded.
Optic nerve and macular imaging was performed in the 
Department of Ophthalmology at Weill Cornell Medical 
College. Both eyes of each patient with PD and controls 
were imaged with the high-resolution, SD-OCT Heidelberg 
Spectralis® HRA + OCT (Heidelberg Engineering, Heidel-
berg, Germany) by a trained operator. Scanning protocols 
included a circular 3.4 mm scan centered on the optic nerve 
head, a volumetric scan of the macula centered on the fovea 
(73 horizontal B-scans covering a superior-to-inferior dis-
tance of 4.6 mm), and a section scan through the fovea. Poor 
quality images were excluded from final analysis.
RNFL, IRL, and macular thickness were measured 
for each eye using the Heidelberg Eye Explorer software 
(Version 1.6.2.0). Each scan was individually reviewed and 
segmentation lines were adjusted to ensure accuracy in both 
RNFL and macular thickness measurements. RNFL measure-
ments were recorded by sector, ie, temporal, superotemporal, 
superonasal, nasal, inferonasal, inferotemporal, and average 
(Figure 2), and compared with the Heidelberg normative 
database. Macular thickness was reported in a modified Early 
Treatment of Diabetic Retinopathy Study macular map with 
the central subfield 1.00 mm in diameter, and the inner and 
outer subfields having diameters of 2.22 mm and 3.45 mm, 
respectively (Figure 3), and compared with published nor-
mals.11 IRL thickness measurements were determined for 
PD subjects, as well as age-matched controls, by manually 
segmenting the IRL (because no normal values for IRL have 
been published). This was accomplished using Heidelberg 
software by setting the inner limit of the IRL at the internal 
limiting membrane, and the outer limit at the outer border 
of the inner nuclear layer (Figure 1) and measuring the verti-
cal thickness at 13 points at 500 μm intervals along a 6 mm 
horizontal section through the fovea (Figure 4).
Mann-Whitney U tests were performed to detect differ-
ences between IRL thickness in PD patients versus controls, 
and macular thickness versus published normals. A one-
  sample t-test was used to detect differences in RNFL thickness 
between PD patients and normal values from the Heidelberg 
database. Statistical analyses were performed using Stata/
IC 11.0 (StataCorp, College Station, TX).
Results
OCT imaging of the optic nerve and macula was performed 
on 18 eyes of nine patients with PD and 19 eyes of 16   controls 
Figure 1 OCT image of the retina of the left eye. The layers of the inner retinal 
layer (IRL) are shown: retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), 
inner plexiform layer (iPL), and inner nuclear layer (inL). Dopaminergic cells have 
been isolated primarily to the inL of the primate retina.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 2 screen grab from the heidelberg eye explorer software automated analysis of the rnFL thickness. A) infrared image showing the location of the circular scan 
(green circle) centered around the optic nerve (green cross) of the right eye. B) Circular optical coherence tomography image of the retina showing the rnFL segmented 
(red lines). C) rnFL thickness measurements in seven sectors as measured by the software. D) Plot of patient’s rnFL thickness (black line) plotted against normative values 
(colored lines). 
Abbreviation: rnFL, retinal nerve fiber layer.
Figure 3 screen grab from the heidelberg eye explorer software analysis of macular thickness. infrared image (A) of the posterior pole of the right eye of a Parkinson’s 
disease patient with superimposed thickness map (multicolored box) and grid corresponding to the nine subfields measured in (B).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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(Table 1). All images were of acceptable quality for inclusion 
in the study. The average age of PD patients was 64 years 
with a range of 52–75 years. The average age of controls was 
67 years with a range of 50–81 years. Of PD patients included 
in the study, 44% were female, while 38% of controls were 
female. Severity ratings for PD patients in the study were in 
the range 1–3 using the modified Hoehn and Yahr scale, with 
two patients having Stage 3 disease, four patients having Stage 
2 disease, and three patients having Stage 1 disease.12
No significant differences were found in IRL thickness 
at any of the 13 points between PD patients and controls in 
our study (Table 2). Overall, average IRL thickness in PD 
patients was actually greater at all but two points measured 
along the 6 mm section through the fovea, although no dif-
ferences reached statistical significance.
The mean central subfield thickness for all eyes was 
276 μm, compared with 270 μm for Heidelberg device-
specific published normative data for patients over the age 
of 60 years.11 Significant differences (P . 0.05) in macular 
thickness were detected in three of nine subfields between 
PD patients and published normal values. In PD subjects, 
the outer superior subfield was 2.8% thinner (P = 0.026), 
while the outer nasal and inner inferior subfields were 2.8%   
(P = 0.016) and 2.7% (P = 0.001) thicker than published 
normal values, respectively (Table 3). No significant differ-
ences were detected in the other six subfields. Applying a 
Bonferroni correction, which decreases false positives but 
increases false negatives, sets the P value at 0.0056, at which 
only the inner inferior subfield reaches significance.
No significant differences were detected in RNFL thick-
ness between PD patients and the Heidelberg normative 
database values (Table 4). Overall average RNFL thickness 
was 97 μm for PD patients, which matched the normative 
database value exactly.
Discussion
To our knowledge, this pilot study is one of the first studies 
to utilize high-resolution SD-OCT with both automated and 
Figure 4 high-resolution spectral-domain optical coherence tomography image of a 
section through the fovea of the right eye of a control patient showing segmentation 
of the inner retinal layer (red lines). Yellow arrowheads correspond to the 13 points 
at which the irL was measured in Parkinson’s disease patients and age-matched 
controls in the study. These points were equally spaced at 500 μm intervals along a 
6 mm horizontal line centered on the fovea.
Table 1 Patient demographics
PD Controls
eyes (n) 18 19
Patients (n) 9 16
Females (n, %)  5 (56%) 10 (62%)
Average age  64 67
Age range  52–75 50–81
Abbreviation: PD, Parkinson’s disease.
Table  2  Mean  inner  retinal  thickness  in  Parkinson’s  disease 
patients versus controls
Location  Inner retinal thickness 
(μm)
P  
(Mann- 
Whitney U) 
  PD Control
Fovea  49 (±36) 46 (±31) 0.704
Temporal 0.5  107 (±15) 107 (±20) 0.738
Temporal 1.0 150 (±10) 145 (±16) 0.280
Temporal 1.5  145 (±11) 141 (±15) 0.181
Temporal 2.0  126 (±10) 124 (±18) 0.648
Temporal 2.5 113 (±8) 115 (±15) 0.616
Temporal 3.0  105 (±8) 103 (±11) 0.761
nasal 0.5  122 (±18) 111 (±26) 0.136
nasal 1.0  163 (±9) 160 (±18) 0.171
nasal 1.5  158 (±9) 164 (±20) 0.353
nasal 2.0  149 (±14) 149 (±19) 1.00
nasal 2.5  144 (±16) 139 (±19) 0.224
nasal 3.0 155 (±19) 146 (±19) 0.121
Notes: Mean irL thickness measurements in μm as measured with the heidelberg 
spectralis® hrA + OCT in patients with PD and age-matched controls. Mann-
Whitney U test used to detect differences (P # 0.05).
Abbreviations: PD, Parkinson’s disease; irL, inner retinal layer.
Table 3 Mean macular thickness in Parkinson’s disease patients 
versus published normal values
Location Mean macular thickness (μm)
PD 
(n = 18)
Normalsa . 60 
(n = 11)
P 
(Mann- 
Whitney U) 
Central subfield 276 263 0.150
inner temporal 325 332 0.156
inner superior 335 329 0.322
inner nasal 336 326 0.059
inner inferior 334 316 0.001
Outer temporal 313 322 0.105
Outer superior 321 332 0.026
Outer nasal 331 320 0.016
Outer inferior 316 314 0.605
Notes:  Mean  macular  thickness  measurements  in  μm  as  measured  with  the 
heidelberg spectralis® hrA+OCT in patients with Parkinson’s disease compared 
with published normal values of subjects over the age of 60. A Mann-Whitney U test 
was used to detect differences. Significance levels can be set at P , 0.05 (greater 
potential for false positives) or P , 0.0056 using a Bonferroni correction (greater 
potential for false negatives). agrover et al.11 
Abbreviation: PD, Parkinson’s disease.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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manual segmentation to examine retinal changes in PD.7–9 
Hajee et al demonstrated thinning of the inner ganglion 
complex (as defined by the specific OCT manufacturer) in 
PD patients using autosegmentation OCT scans.9 Using lower 
resolution time-domain OCTs, Altinas et al showed reduced 
macular volume, macular thickness, and RNFL thickness 
in PD patients, and Inzelberg et al demonstrated significant 
RNFL thinning in PD patients.7,11
Our study failed to show significant reductions in IRL 
thickness between PD patients and age-matched controls. In 
fact, our results showed PD patients to have a slightly greater 
IRL thickness at 11 of 13 points along a section through the 
fovea, although none of these reached significance. More-
over, no significant differences were found in RNFL thick-
ness between PD patients and normal values.
However, our results did show significant differences in 
macular thickness at three of nine subfields, including the 
outer superior, outer inferior, and outer nasal subfields. One 
of the three subfields showed decreased macular thickness in 
the PD patients compared to published normal values, while 
two showed significant increases in macular thickness. This 
did not agree with the findings of Altinas et al, which showed 
thinning of the outer inferior, outer nasal, outer temporal, and 
inner superior subfields, and found no significant difference 
in the outer superior subfield.8
Overall, as a small pilot study, this study is limited by 
the small number of eyes included. However, our sample 
size of nine patients does not differ greatly from previ-
ously published studies (10 patients for Inzelberg et al, 17 
patients for Altinas et al, and 24 patients for Hajee et al). 
A larger cohort of patients, followed prospectively, and 
examined with high-resolution SD-OCT, is necessary to 
clarify the precise relationship between retinal structural 
changes and PD.
A strength of the current analysis lies in its use of SD-OCT 
as opposed to time-domain OCT. The increased resolution of 
SD-OCT allows for more precise and   accurate measurements 
of retinal layer thickness. SD-OCT also offers other advan-
tages, ie, true volumetric calculations due to significantly 
less interpolation, image registration enabling accurate and 
reproducible long-term monitoring, and improved image 
segmentation facilitating analysis of specific retinal layers. 
Moreover, our study, in addition to the automated segmenta-
tion, utilized manual segmentation, enabling more accurate 
measurements of specific retinal layers (especially the IRL 
for which there is currently no automated segmentation). 
Although automated segmentation with SD-OCT is consider-
ably more reliable than TD-OCT, even with high-resolution 
OCT, the not infrequent occurrence of segmentation errors 
is a confounding factor in OCT analysis of PD patients.14 
Lastly, unlike previous studies, for the macular thickness 
and RNFL comparisons, we evaluated the measurements in 
PD in relation to that of the large, validated, and normalized 
control database provided by the manufacturer (and used 
routinely for such analysis in glaucoma patients). Previous 
studies in PD patients used considerably smaller populations 
of “control” patients typically recruited from other patients 
who presented to the ophthalmologist.
Overall, our findings do not suggest that IRL thickness 
or RNFL thickness is reduced at a detectable level with the 
Heidelberg Spectralis SD-OCT in PD patients. Our results 
do suggest, however, that changes in overall macular volume 
may be detectable at specific subfields, which suggests that 
SD-OCT could potentially be correlated with disease sever-
ity and used as a biomarker for PD progression. However, 
as with all previous OCT studies in PD patients, this study 
involved a small cohort of patients, and these and other 
results should be viewed as preliminary findings. Larger, 
longitudinal, prospective studies are needed to explore further 
the potential relationship between retinal findings and OCT 
measurements. Until such studies are undertaken, the routine 
clinical use of OCT for evaluation of PD patients must be 
taken with great caution.
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Table 4 Mean retinal nerve fiber layer thickness in Parkinson’s 
disease patients versus normal values
Location Mean RNFL thickness  
(μm)
P   (one-sample  
t-test)
PD Normalsa  
T 71 74 0.315
sT 130 134 0.306
sn 106 102 0.550
n 74 72 0.613
in 113 105 0.363
iT 139 141 0.593
Average 97 97 0.911
Notes: Mean retinal nerve fiber layer (RNFL) thickness measurements in μm as 
measured with the heidelberg spectralis® hrA+OCT in patients with Parkinson’s 
disease compared with normal values from the heidelgberg database. A one-sample 
t-test was used to detect differences (P # 0.05).
Abbreviations: RNFL, retinal nerve fiber layer; T, temporal; ST, superior temporal; 
sn, superior nasal; n, nasal; in, inferior nasal; iT, inferior temporal; PD, Parkinson’s 
disease.Clinical Ophthalmology
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